Stocksigma LogoStocksigma Logo

Veerhealth Care Reports Strong H1FY27 Growth and USFDA Clearance

Veerhealth Care reported robust H1FY27 standalone results with revenue from operations surging 458.21% YoY to ₹47.28 crore, EBITDA rising 200.73% YoY to

Veerhealth Care Reports Strong H1FY27 Growth and USFDA Clearance

Veerhealth Care Ltd · Press Release · 16 Nov 2026, 10:28 pm

Veerhealth Care Reports Strong H1FY27 Growth and USFDA Clearance Veerhealth Care reported robust H1FY27 standalone results with revenue from operations surging 458.21% YoY to ₹47.28 crore, EBITDA rising 200.73% YoY to ₹4.12 crore, and net profit up 397.96% YoY to ₹2.44 crore. FY27 guidance projects total income of ₹105 crore with PAT of ₹5-7 crore, expanding to ₹156 crore and PAT of ₹9-11 crore in FY28. Growth catalysts include USFDA clearance for OTC drug exports to the US, key export order wins, entry into Russia, and expanded domestic e-commerce distribution across major platforms.

Original exchange filing (PDF)

More announcements from Veerhealth Care Ltd

All Veerhealth Care Ltd announcements